Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00505297
Previous Study | Return to List | Next Study

A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00505297
Recruitment Status : Completed
First Posted : July 23, 2007
Last Update Posted : July 23, 2007
Sponsor:
Collaborator:
Pfizer
Information provided by:
University of California, San Francisco

Tracking Information
First Submitted Date July 20, 2007
First Posted Date July 23, 2007
Last Update Posted Date July 23, 2007
Study Start Date August 2004
Primary Completion Date Not Provided
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography
Official Title A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography
Brief Summary In order to design future disease modifying osteoarthritis drug (DMOAD) proof of concept studies, this study is being conducted to assess magnetic resonance imaging (MRI) measurements of cartilage morphology and glycosaminoglycan (GAG) content as it relates to the progression of disease in subjects with potentially rapidly progressing OA. The subject population is selected to have higher likelihood of having rapidly progressing OA (i.e., a more rapid joint space narrowing (JSN) compared to general knee OA population and thus, may be more likely to have changes in GAG content and/or cartilage volume. The results of this study may provide a reasonable means to assess DMOAD activity of drugs in development. The non-OA controls are included to determine the rate of change for subjects of similar age. Ideally, results of this study will identify reliable methods for delayed Gadolinium Enhanced MRI of cartilage (dGEMRIC) and MRI cartilage assessment that correlate with OA disease progression as compared to x-ray changes.
Detailed Description

The objective of the study are:

  • Evaluate OA progression by evaluating cartilage morphology, cartilage glycosaminoglycan (GAG) content, and joint space changes measured by MRI (3.0T), dGEMRIC index, and radiography, respectively using age-matched control subjects to identify disease related changes.
  • Identify subject characteristics associated with more rapidly progressing OA.
  • Identify most sensitive efficacy endpoints for future DMOAD proof of concept (POC) studies.
  • Establish time interval for future studies based on MRI endpoints.
  • Evaluate the effect of contrast agent on MRI cartilage morphology and T2 measurements
  • Define criteria for classifying cartilage legions/deficits using dGEMRIC and T2 measurements.
  • Collect biofluid samples for future validation of disease specific biomarkers.
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Osteoarthritis
Intervention Not Provided
Study Groups/Cohorts
  • A
    Subjects with potentiall rapidl progressing OA
  • B
    Age-matched healthy subjects with no knee pain
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July¬†20,¬†2007)
18
Original Actual Enrollment Same as current
Actual Study Completion Date July 2007
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Female patients evaluated to be relatively in good health
  • 40 years old and above
  • Negative pregnancy test

Additional inclusion criteria for OA patients:

  • Frequent knee symptoms in the past year, defined as:
  • pain, aching, or stiffness on most days of a month during the past year
  • use od medication (all types) for treatment of knee pain on most days of a month during the past year
  • Kellgren & Lawrence Grades 2 or 3 of the study knee (with either the same or less severe OA , or no OA in the contralateral knee)
  • Body mass index (BMI) of 30 and above
  • Medial joint space width of 2 mm and above

Additional inclusion criteria for age-matched controls:

  • BMI of 28 and above
  • No evidence of knee OA in either knee (i.e., Kellgren & Lawrence Grade 0 diagnosed by x-ray on AP view; infrequent knee pain, aching, stiffness during the past year; infrequent use of medication (all types) for treatment of knee pain during the past year.

Exclusion Criteria:

  • Anticipated need for knee surgery in the next 2 years
  • OA predominantly in the lateral tibiofemoral compartment measured by PA x-ray view of the study knee
  • Intra-articular steroids to study joint (3 month washout), intra-articular hyaluronic acid to the study joint (3 month-washout), doxycycline (3 month washout), or arthroscopy within the last 6 months
  • Medial joint space width less than 2 mm measured by PA view of knee x-ray
  • History of joint replacement, intra-articular fracture, osteotomy, arthroplasty, or meniscectomy of the study knee
  • History of other diseases that may involve the study joint including inflammatory joint diseases, crystalline disease, endocrinopathies, metabolic, diseases, knee infection of the study knee, neuropathic disorders, avascular necrosis, Paget's disease, or tumors (chondrocalcinosis is acceptable; treated thyroid disease is acceptable)
  • Systemic inflammatory diseases (e.g., Rheumatoid arthritis)
  • Other pain that the principal investigator feels can not be distinguished from knee pain (e.g., lumbar pain, hip pain, trochanteric bursitis)
  • Musculoskeletal pain that may preclude the subject from remaining motionless for the MRI acquisitions
  • Unable to undergo an MRI exam of the knee because of contraindications
  • Unable to receive gadopentate contrast agent injection because of contraindications. A study subject who displays any sign of an allergic reaction to the contrast agent will be withdrawn from the dGEMRIC part of the protocol and will not receive any subsequent contrast agent injection. The subject may continue to complete the remainder fo the study, which includes MR morphometry scan, collection of blood and urine sample for biomarker assays, and completion of study questionnaires.
  • Clinical chemistry laboratory values more than 2 times the upper limit of normal
  • Participation in clinical trial with a study during in the past 14 days
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry in the this trial
Sex/Gender
Sexes Eligible for Study: Female
Ages 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00505297
Other Study ID Numbers A9001140
H6513-25393
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor University of California, San Francisco
Collaborators Pfizer
Investigators
Principal Investigator: Sharmila Majumdar, PhD University of California, San Francisco
Principal Investigator: Thomas M. Link, M.D. University of California, San Francisco
PRS Account University of California, San Francisco
Verification Date October 2006